Abstract
Excessive glutamatergic transmission is thought to be responsible for the injury observed in a variety of neurological disorders such as stroke. N-acetylaspartylglutamate (NAAG), a major peptidic component of the brain, has been suggested to serve as a potential storage form of glutamate. N-acetylated-a-linked acidic dipeptidase (NAALADase, EC 3.4.17.21) is responsible for the hydrolysis of NAAG into N-acetylaspartate (NAA) and glutamate. If NAAG is a storage form of glutamate, then inhibition of NAALADase should be neuroprotective in diseases in which excess glutamatergic transmission is detrimental. In addition, NAAG has been demonstrated to be an agonist at group II metabotropic glutamate receptors and functions as a mixed agonist antagonist at N-methyl-D-aspartate receptors. Therefore, inhibition of NAALADase would also function to increase NAAG levels which, in turn, should provide neuroprotection via the interaction of NAAG with these receptors. Recently, potent and selective inhibitors of the enzyme have been designed and subsequently used to demonstrate that inhibition of NAALADase is neuroprotective in animal models of neurodegeneration. As such, NAALADase inhibition represents a novel method of regulating extracellular glutamate levels and provides a new avenue for the treatment of neurological disorders.
Keywords: NAALADase Inhibitors, Neuroprotective Strategy, glutamatergic transmission, N-acetylaspartylglutamate NAAG, N-acetylated-a-linked acidic dipeptidase NAALADase, N-acetylaspartate, NAALADase INHIBITOR, PHOSPHORUS
Current Medicinal Chemistry
Title: Design of NAALADase Inhibitors A Novel Neuroprotective Strategy
Volume: 8 Issue: 8
Author(s): Paul F. Jackson and Barbara S. Slusher
Affiliation:
Keywords: NAALADase Inhibitors, Neuroprotective Strategy, glutamatergic transmission, N-acetylaspartylglutamate NAAG, N-acetylated-a-linked acidic dipeptidase NAALADase, N-acetylaspartate, NAALADase INHIBITOR, PHOSPHORUS
Abstract: Excessive glutamatergic transmission is thought to be responsible for the injury observed in a variety of neurological disorders such as stroke. N-acetylaspartylglutamate (NAAG), a major peptidic component of the brain, has been suggested to serve as a potential storage form of glutamate. N-acetylated-a-linked acidic dipeptidase (NAALADase, EC 3.4.17.21) is responsible for the hydrolysis of NAAG into N-acetylaspartate (NAA) and glutamate. If NAAG is a storage form of glutamate, then inhibition of NAALADase should be neuroprotective in diseases in which excess glutamatergic transmission is detrimental. In addition, NAAG has been demonstrated to be an agonist at group II metabotropic glutamate receptors and functions as a mixed agonist antagonist at N-methyl-D-aspartate receptors. Therefore, inhibition of NAALADase would also function to increase NAAG levels which, in turn, should provide neuroprotection via the interaction of NAAG with these receptors. Recently, potent and selective inhibitors of the enzyme have been designed and subsequently used to demonstrate that inhibition of NAALADase is neuroprotective in animal models of neurodegeneration. As such, NAALADase inhibition represents a novel method of regulating extracellular glutamate levels and provides a new avenue for the treatment of neurological disorders.
Export Options
About this article
Cite this article as:
Jackson F. Paul and Slusher S. Barbara, Design of NAALADase Inhibitors A Novel Neuroprotective Strategy, Current Medicinal Chemistry 2001; 8 (8) . https://dx.doi.org/10.2174/0929867013372797
DOI https://dx.doi.org/10.2174/0929867013372797 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Synthesis and Antiproliferative Activity of Coumarin-Estrogen Conjugates against Breast Cancer Cell Lines
Letters in Drug Design & Discovery Meet Our Editorial Board Member:
Current Drug Targets New Benzothiazole/thiazole-Containing Hydroxamic Acids as Potent Histone Deacetylase Inhibitors and Antitumor Agents
Medicinal Chemistry Peptide Phage Display: Opportunities for Development of Personalized Anti-Cancer Strategies
Anti-Cancer Agents in Medicinal Chemistry Virtual Screening of NCI Diversity Set II Lead to New Cyclin-Dependent Kinases 5 Inhibitors Using AutoDock
Letters in Drug Design & Discovery Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Development of Radiofrequency Saturation Amplitude-independent Quantitative Markers for Magnetization Transfer MRI of Prostate Cancer
Current Medical Imaging Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design Design, Synthesis and Anticancer Activity Evaluation of Diazepinomicin Derivatives
Letters in Drug Design & Discovery Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Role of Stem Cells in Normal Liver and Cancer
Anti-Cancer Agents in Medicinal Chemistry Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease
Current Pharmaceutical Design Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design Cancer Chemoprevention with Green Tea Catechins: From Bench to Bed
Current Drug Targets Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design Phycobilins and Phycobiliproteins Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Antibody-Based Imaging of HER-2: Moving into the Clinic
Current Molecular Medicine